Senior Management

writing Dr Alan Roach is a pharmacologist by training and has worked in various aspects of drug discovery and development in big pharma since 1974. Alan started his research career at Synthélabo and worked subsequently at Reckitt & Coleman, Glaxo and Rhône-Poulenc Rorer and latterly Aventis. He was a key member of the senior management team at Argenta Discovery where he was one of the scientific founders of the company. At the outset of Argenta Discovery in 2000, Alan was initially responsible for Business Development to ensure consolidation of the company and subsequently reverted back to research as Director of Therapeutics where he successfully started programmes in cancer, diabetes, obesity and allergy/asthma and inflammation. He joined DanioLabs in 2005 as Head of Therapeutics and became Senior Director of Research at Summit plc after DanioLabs acquisition by VASTox (latterly Summit plc). Alan left Summit plc in January 2009 and went on to co-found Vastrata Ltd. In his career Alan has worked on several discovery projects that have taken compounds through to clinical development and even through to the market place. Alan is an author on over 90 peer reviewed publications and patents.
Dr Paul Goldsmith is a practising Consultant Neurologist with a PhD in human disease modeling. From this work he co-founded DanioLabs Ltd in 2002 and became its CSO. In his role as CSO, Paul had overall responsibility for the company’s scientific and clinical strategy. The most advanced reprofiling project now has positive Phase 2 clinical data. After the acquisition of DanioLabs by VASTox, Paul was part of the re-launch team behind Ieso Health, before going on to co-found Rubrum Ltd. He is an author of over 50 peer reviewed publications and patents. writing

Advisory group

writing Dr Hans Fliri has held a variety of senior management positions in global pharmaceutical and biotechnology companies. He has worked in various research and management positions at Sandoz (now Novartis) between 1977 and 1994. He was then appointed Senior Director of anti-infective drug discovery and lead generation at Rhone-Poulenc Rorer and later Aventis in Paris (1994-2000). He was then recruited to the position of Vice President of drug discovery at Cetek Corporation (2001-2002) in the US prior. He then joined Scynexis Europe, leading the MBO in 2006, at which point it changed its name to Selcia. He was CEO from 2003 to 2013, when he moved to the position of Chairman. Hans has also served on scientific advisory boards for several companies in Europe and the US. He holds a PhD in chemistry from the University of Innsbruck and is the author of approximately 50 scientific articles and patents.
Dr Chris Newton held senior management positions in the Rhone-Poulenc group of companies between 1979 and 2000, delivering a number of clinical programs into development, one of which was successfully developed into a marketed drug (temozolomide, Temodal®). Between 2000 and 2005, he was a founding scientist, CSO and Board Director at Argenta Discovery Ltd. Between 2005 and 2010 he was managing Director, BioFocus DPI, responsible for the contract research centres in the UK, Switzerland, Germany, the Netherlands and the USA. Between 2010 and 2013 he had the position of SVP Galapagos Services, being responsible for some 300 scientists in the UK and Netherlands performing contract drug discovery within the twin CROs: Argenta and BioFocus. He holds a degree in Natural Sciences from the University of Cambridge and a PhD from the University of Sheffield. Chris is the author and inventor of approximately 50 publications and patents. writing

Patent counsel

Dr Vince Price is of Counsel, EIP Life practice group, with many years of experience in patent drafting, prosecution, opposition and appeal proceedings, having previously built a practice as a partner in a major UK firm and more recently as proprietor of Price & Co, a boutique practice specialising in biotechnology. writing